Caboxen 80 mg, containing the active ingredient Cabozantinib, is an advanced tyrosine kinase inhibitor (TKI) designed for the treatment of various cancers, including advanced renal cell carcinoma (RCC) and hepatocellular carcinoma (HCC). As a multi-kinase inhibitor, Caboxen targets several critical pathways involved in tumor growth, angiogenesis, and metastasis, including VEGFRs, MET, and AXL. Manufactured under stringent pharmaceutical standards, Caboxen represents a significant innovation in oncology therapeutics, providing a targeted treatment option for patients with advanced cancers.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Therapeutic Class

• Targeted Cancer Therapy / Tyrosine Kinase Inhibitor

Indications

Caboxen 80 mg is indicated for:

• Advanced renal cell carcinoma (RCC) in adults who have received prior anti-angiogenic therapy

• Hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib

Caboxen may also be used for other cancers under clinical supervision or in ongoing trials, as guided by oncologists.

Pharmacology

Cabozantinib is a multi-targeted TKI that inhibits key kinases involved in tumor proliferation and angiogenesis:

• VEGFR1-3: Prevents formation of new blood vessels that supply tumors

• MET and AXL: Reduces tumor growth, metastasis, and resistance to therapy

• By inhibiting these pathways, Cabozantinib slows tumor progression, reduces metastasis, and can improve survival outcomes in patients with RCC and HCC.

Pharmacokinetics:

• Absorption: Peak plasma concentration occurs 2–5 hours after oral administration

• Metabolism: Primarily via CYP3A4, with caution required when co-administered with CYP3A4 modulators

• Half-life: Approximately 99 hours, supporting once-daily dosing

Dosage & Administration

• Recommended dose: 80 mg orally, once daily, with or without food

• Tablets should be swallowed whole; do not crush or chew

• Continue treatment until disease progression or unacceptable toxicity occurs

• Missed dose: Take the next dose at the scheduled time; do not double the dose to compensate

• Dose adjustments may be required for adverse reactions such as hypertension, hand-foot syndrome, diarrhea, or elevated liver enzymes

Interactions

• CYP3A4 inhibitors (e.g., ketoconazole) may increase Cabozantinib exposure; monitor for toxicity

• CYP3A4 inducers (e.g., rifampicin) may reduce efficacy

• Avoid co-administration with drugs that prolong QT interval or have narrow therapeutic windows without monitoring

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Side Effects

Common adverse effects include:

• Gastrointestinal: Diarrhea, nausea, vomiting

• Dermatologic: Hand-foot syndrome, rash

• Cardiovascular: Hypertension

• Hematologic: Fatigue, anemia, thrombocytopenia

• Hepatic: Elevated liver enzymes

Serious but less frequent side effects include hemorrhage, gastrointestinal perforation, and cardiac events, requiring close monitoring.

Pregnancy & Lactation

• Cabozantinib may cause fetal harm; not recommended during pregnancy

• Effective contraception is required during treatment and for 4 months after the last dose

• Breastfeeding should be avoided during treatment and for a defined washout period

Precautions & Warnings

• Monitor blood pressure, liver function, and electrolytes regularly

• Interrupt or reduce dosage for severe toxicities such as GI perforation, hemorrhage, or severe hypertension

• Patients should be counseled on sun protection due to photosensitivity risks

Use in Special Populations

• No dose adjustment required for mild to moderate renal or hepatic impairment

• Safety in pediatric patients is not established

• Limited data for elderly patients, though tolerability is generally consistent with younger adults

Storage Conditions

• Store below 30°C, in a dry and dark place

• Keep out of reach of children

• Protect tablets from moisture and light.